AVCO came out of this morning's opening bell red hot, and after a slight pullback, it could be ready to move again.

SmallCapFirm

Continuing Today's Strong Green Move, Nasdaq Profile (AVCO) Needs Full Attention Now

October 10th

SCF Readers,

AVCO came out of this morning's opening bell red hot, and after a slight pullback, it could be ready to move again.

With a $.56 high under its belt already, AVCO has since pulled back to a $.47 low.

But since that time, it has now popped back over the $.50+ mark.

After this initial resistance, could AVCO be ready to make another vertical push?

4 key lines of potential support are slightly above where AVCO is trading at the moment. Those include its:

  • 5-Day Simple Moving Average (SMA)
  • 20-Day SMA
  • 5-Day Exponential Moving Average (EMA)
  • 13-Day EMA

If resistance breaks down at those levels and becomes strong support, it could act as building blocks for AVCO to return to previous highs in the near term.

Drop what you're doing to make sure AVCO has top spot on your watch-list today.

-----

The opening bell will be here sooner rather than later.

With little time to prepare, fire down that coffee quickly because things could get wild today.

Last week I brought two different ideas to your attention.

Most recently, one that ran to a 1-month high and an approximate 18% run from its prior day's close to the following day's high.

That was on the heels of this past Tuesday's pre-market alert that rocketed approximately 38%.

Now, for the main event...

The last time I brought this past champ to your attention, it burst approximately 24% from the previous day's close to the next morning's high.

Since then, it bottomed out and then did something truly stunning...

Made an 88% move in just a handful of days.

WOOF!

And right now, it's bottomed out again...

Plus, hear this. That wasn't the 1st time I alerted this Nasdaq idea.

Previously in 2022, it also shot approximately 20% in just a few short days.

Could the 3rd time be the biggest charm of all?

Based on its explosive chart history, its low float, and several technical indicators that could be signaling a possible healthy reversal could be nearing, this Nasdaq past champ requires full focus going into Monday's opening bell.

Right now drop everything to get this profile to the top of your watch-list:

*Avalon GloboCare Corp. (AVCO)*

Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome-based ACTEX technology, as well as cell therapy related companion diagnostics.

And right now, AVCO has 5 potential breakout catalysts that are must-know material. Check them out:

No. 1 - Low Float Profile With Explosive Chart History

No. 2 - Company Receives Notice Of Allowance Related To QTY Protein Platform

No. 3 - Oversold Bounce/Reversal? Key Days Lie Ahead

No. 4 - New Publication In Top-Ranked Journal Is Turning Heads

No. 5 - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech

But more on those in a second...

It All Starts With Your Body’s T-Cells…

They’re your immune system’s frontline soldiers in the fight against common infections and everyday maladies.

When you’re stuck at home on bedrest, your T-Cells are hard at work getting you back into healthy shape.

Though, they may not always be ready to take on the tougher conditions.

That’s where Chimeric Antigen Receptor T-Cell (or “CAR-T”) therapy comes in.

Experts refer to CAR-T therapy as a potential “Living Cure” for some of the world’s deadliest diseases.

Even in its earliest forms as a treatment for blood cancer, this relatively non-invasive treatment leads to lasting remission in no less than 30-40% of patients.

But one company could potentially drive that success rate much higher…

Avalon GloboCare’s Revolutionary Research

image

Avalon is a clinical-stage, vertically integrated, leading “CellTech” bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well related diagnostics and therapeutics.

The Company also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and other related vaccine and therapeutics.

Their core focus at the moment is their 3rd Generation CAR-T therapy that can potentially be useful in the treatment of cancer and other life-threatening diseases along with their FLASH-CAR technology and stem cell derived Exosome technology called ACTEX. ACTEX can be used to treat a wide variety of conditions, from neurodegenerative disorders to immune health, orthopedic applications, wound management and even weight management.

Avalon GloboCare successfully filed for a $50Mn shelf offering (S3) in January of 2019, and was also staked a $20Mn credit facility from Chairman Daniel Lu.

That same Daniel Lu also happens to be chairman of the Lu DaoPei hospital group, China’s largest hematology and CAR-T treatment center.

Those types of connections are key to Avalon GloboCare’s vertical integration:

Upstream: Innovation, R&D, IPs

- QTY-code engineered novel targets; AVA-Trap ™

- Next-Gen multi-target, RNA-based Flash-CAR ™

- Angiogenic Exosomes; ACTEX ™

Midstream: Process development, Bio-production, QC/QA

- UPMC: Accredited cGMP/cGTP/FACT/aaBB/CLIA/CAP Facility

Downstream: Clinical Programs

- Medical Team: Lu Daopei Hospital network and over 100 affiliated hospitals, the world’s single largest BMT and CAR-T treatment center;

- Commercialization: B-to-B model for product development and global marketing (ACTEX ™ecosystem)

This kind of integration is a tremendous advantage for companies working in the clinical stage of the process, because it gives Avalon GloboCare a real-world path to market (and to potential revenues) without the imminent need to involve third parties or secure new funding.

That means the company has a direct pipeline that can take compelling research and new ideas, rapidly transform them into a marketable product, and then potentially fast-track the testing process.

Their lead CAR-T candidate, AVA-001, has already completed a pilot first-in-human trial in patients with B-cell acute lymphoblastic leukemia with a stated remission rate far higher than the industry standard.

Avalon is currently expanding patient recruitment and indication.

Read more key details at the company website and check out their presentation here.

-----

And right now, 5 potential catalysts could fuel a vertical chart move in the near term for AVCO. They are:

No. 1 AVCO Potential Catalyst - Low Float Profile With Explosive Chart History

Check out AVCO's 3-month chart below:

image

Above you can see how quickly this profile can make explosive moves.

From a July 21st low of $.4225, AVCO made a move to a high of $.8050 two weeks late on August 4th.

Boom. 90% just like that.

That was followed up soon after by a move from September 26th low of $.42 to a September 30th high of $.79.

88% in less than a week.

But how is that possible? Simple. AVCO has a relatively low float.

With Yahoo Finance reporting this profile to have approximately 37.78Mn shares in its float, volatility could rear its head on a daily basis.

The point is this: You'll want to watch AVCO closely.

-----

No. 2 AVCO Potential Catalyst - Company Receives Notice Of Allowance Related To QTY Protein Platform

Avalon GloboCare Receives Allowance for Joint U.S. Patent

Jointly with MIT, the Company also Submitted a New U.S. Patent Application for QTY Glucose Transporters

FREEHOLD, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today provided an update regarding the Company’s intellectual property portfolio featuring its QTY protein code technology.

The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.

The Company also submitted a new patent application to the USPTO related to its QTY glucose transporter technology. This patent application was also jointly filed with Dr. Shuguang Zhang of MIT. QTY glucose transporters are deregulated in many tumor types and are potentially important targets for cancer therapy.

The “QTY Code,” is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, enabling their potential use in many clinical applications, including drug development.

Avalon’s proprietary AVA-Trap™ technology utilizes the artificial intelligence (AI) enhanced QTY Code technology to turn receptor molecules into antibody-like decoy receptors that are able to mop up cytokines and chemokines, which are excessively produced during pathological conditions, such as CV-19 and cancer metastasis.

We continue to strengthen our IP portfolio as we believe our novel QTY code protein design technology holds great potential for biotechnology applications and could generate significant clinical advancements in cellular immunotherapy and immune-oncology,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Our AI-enhanced protein design QTY Code technology co-developed with MIT’s Dr. Zhang is a novel platform that produces water-soluble proteins for a wide spectrum of biomedical applications including the design and construction of novel targets for application in cellular immunotherapy.

We are also pleased to submit a new patent application to the USPTO related to QTY glucose transporters, which are important cancer therapy targets. We believe using the QTY technology will accelerate our understanding of these proteins and the development of antibodies against them to treat cancer,” said Dr. Jin.

Read the full article here.

-----

No. 3 AVCO Potential Catalyst - Oversold Bounce/Reversal? Key Days Lie Ahead

As of close Friday, Barchart was reporting this profile to have several oversold leaning technicals.

These technicals could be signaling a healthy reversal could be approaching in the near term.

Here's the definition of a "reversal" from Investopedia:

"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."

Now, here are some key technicals (as of close Friday) that could signal AVCO to be leaning oversold and on the verge of a potential reversal.

  • 14-Day Raw Stochastic: 13.51%
  • 14-Day Williams %R: 86.49%

As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

-----

No. 4 AVCO Potential Catalyst - New Publication In Top-Ranked Journal Is Turning Heads

Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society

Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications

Reports plans to apply for additional patents related to QTY code applications jointly with MIT

FREEHOLD, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new publication featuring the Company’s QTY protein code technology in Chemical Reviews, a top-ranked peer-reviewed scientific journal and the official journal of American Chemical Society (journal Impact Factor is 72). The publication, entitled “Protein Design: From the Aspect of Water Solubility and Stability,” focuses on the innovative QTY protein design code—co-developed by Avalon—as a novel platform to generate water-soluble proteins for a wide spectrum of biomedical applications. The Company initially licensed the technology from the Massachusetts Institute of Technology (MIT) and has advanced the platform through a sponsored research agreement with the university.

...

We are excited to have the technology we developed together with MIT’s Dr. Zhang featured in this publication,” said David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon. “Over the past 70 years, there has been rapid advancement in the understanding of how biology works at the molecular level. Our QTY protein design code extends this knowledge, enabling an even more precise understanding and manipulation of protein structures and function. Not only does the QTY code contribute significantly to the knowledge base of an important class of proteins, but we believe it also provides new pathways for further investigation and subsequent applications that were previously unattainable. Importantly, we believe this publication is a validation of Avalon’s strategy. We previously licensed patents from MIT related to the use of QTY solubilized membrane proteins to be used as decoy receptors in therapeutics. We subsequently filed additional patent applications jointly with MIT, and plan to apply for more patents with the university related to the QTY protein design technologies.

...

Read the full article here.

-----

No. 5 AVCO Potential Catalyst - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech

Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer.

...

Read the full article here.

-----

AVCO Recap: These Potential Catalysts Could Fuel A Vertical Move For This Nasdaq Profile

No. 1 - Low Float Profile With Explosive Chart History

No. 2 - Company Receives Notice Of Allowance Related To QTY Protein Platform

No. 3 - Oversold Bounce/Reversal? Key Days Lie Ahead

No. 4 - New Publication In Top-Ranked Journal Is Turning Heads

No. 5 - A Game-Changing New Study Featuring AI Enhanced Protein Design "QTY Code" Tech

-----

Coverage is officially initiated on AVCO. When time permits, do this:

image

Get AVCO on your radar now.

Sincerely,

Axel Adams

Editor, SCF


(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​

SmallCapFirm "SCF" (smallcapfirm . com) is owned by SWN Media LLC, a limited liability company. Disclosure: I am not a license d finan.cial advise r. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. SmallCapFirm's full disclosure is to be read and fully understood before using SmallCapFirm's website, or joining SmallCapFirm's email or text list. By viewing SmallCapFirm's website and/or reading SmallCapFirm's email or text newsletter you are agreeing to SmallCapFirm's full disclosure which can be read at: smallcapfirm.com/disclosure An owner of SWN Media LLC owns and operates fierceinvestor . com (“FI”), owns and operates stockwirenews . com ("SWN"), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Ownership of "FI" and "SSW" has now moved to a single individual. Pursuant to an agreement between SWN Media LLC and Legends Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 1/31/22 and ending on 2/1/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 8/3/22 and ending on 8/4/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid seven thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). Pursuant to an agreement between SWN Media LLC and TD Media LLC, SmallCapFirm (SCF) has been hired for a period beginning on 10/9/22 and ending on 10/11/22 to publicly disseminate information about (AVCO) via Website, Email and SMS. SWN Media LLC was paid two thousand five hundred USD via bank wire transfer. We own zero shares of (AVCO). To date we have been compensated a total of thirty-seven thousand five hundred USD via bank wire transfer to disseminate information about (AVCO).